---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-330568"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2026-08-03T20:10:16+00:00"
generated_at: "2026-08-03T20:11:19.056165+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ORIC initiates Himalayas-1 Phase 3 trial for rinzimetostat; Q2 cash $387.6M, R&D $36.3M

## Summary
- Initiated Himalayas-1 global Phase 3 registrational trial for rinzimetostat in mCRPC; ~600 patients, 25 countries, primary endpoint rPFS.
- Entered clinical trial collaboration with Bayer to supply darolutamide at no cost for Himalayas-1; ORIC retains full rights to rinzimetostat.
- Cash and investments $387.6M as of June 30, 2026; includes $59.9M net proceeds from ATM; runway into 2H 2028.
- R&D expenses $36.3M for Q2 2026, up from $30.5M YoY; G&A $9.0M, up from $8.5M.
- Anticipated milestones: rinzimetostat program update 2H 2026; enozertinib data at ESMO October 2026.

## SEC filing metadata
- accession: 0001193125-26-330568
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2026-08-03T20:10:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312526330568/0001193125-26-330568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312526330568/oric-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-330568
- JSON: https://secwatch.observer/filing/0001193125-26-330568.json
- Plain text: https://secwatch.observer/filing/0001193125-26-330568.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.